News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm

October 11, 2023

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER MEASURES.

Stockholm, October 11, 2023. On October 10, 2023 Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) announced that the Company had secured a combined financing of approximately SEK 462 million comprising a private placement (the “Private Placement”) and a debt financing.
 
A prospectus has been prepared due to the Private Placement and has today, October 11, 2023, been approved and registered by the SFSA and is available on the Company’s website, www.egetis.com.
 
Advisers
Bryan, Garnier & Co acted as Sole Global Coordinator & Sole Bookrunner and Advokatfirman Vinge KB acted as Legal Adviser.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]